MBX Biosciences, Inc. (MBX): Total Liabilities
$15.92M
As of 2025-12-31
$26.37M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.92M | +43.5% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $11.09M | +158.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $4.29M | n/a | 2025-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $15.92M | +43.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $141.50M | +146.0% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $71.25M | -27.0% |
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $131.36M | +584.2% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $343.95M | +27.5% |
| Erasca, Inc. (ERAS) | 2025-12-31 | $70.98M | -10.2% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
Compare MBX, ZBIO, XERS, TRDA side by side · Screen every company in Pharmaceutical Preparations ↗